Search Results for “cancer” – Page 155 – media

FDA approves Mevion’s Hyperscan pencil beam scanning technology

Mevion S250i is a compact proton therapy system that has the capacity to deliver conformal radiation therapy treatments with the support of Hyperscan pencil beam scanning technology.
- Source: MDBR
- 538
- January 8, 2018
Company Insight FDA medical device
Next-generation medical scanning

Researchers have developed a new way to magnetise molecules found naturally in the human body, paving the way for a new generation of low-cost magnetic resonance imaging (MRI) technology that would transform our ability to diagnose and treat diseases including cancer, diabetes and dementia.
- Source: ScienceDaily
- 519
- January 8, 2018
medical device MRI Researches
BioNTech raises $270M A round to fuel mRNA, CAR-T R&D

BioNTech has raised $270 million (€224 million). The series A round positions the German biotech to mount a multifront attack on cancer, spearheaded by mRNA therapies and supported by a clutch of other modalities including CAR-T cells.
- Source: fiercebiotech
- 639
- January 5, 2018
CAR-T therapy Company Insight mRNA Series
Precision editing of gut bacteria– Potential way to treat colitis

UT Southwestern Medical Center researchers have used precision editing of the bacterial populations in the gut to prevent or reduce the severity of inflammation in a mouse model of colitis.
- Source: sciencedaily
- 557
- January 5, 2018
colitis gut bacteria Researches
US awards Novartis’ Kisqali ‘Breakthrough’ status

Novartis’ CDK4/6 inhibitor Kisqali has picked up Breakthrough status in the US as an initial endocrine-based treatment in certain patients with breast cancer.
- Source: pharmatimes
- 553
- January 4, 2018
inhibitor Kisqali New Approvals
Scholar Rock scoops $47M to trial SMA drug

Scholar Rock has raised $47 million to take its treatment for spinal muscular atrophy (SMA) into the clinic. The series C tees up Scholar Rock to find out whether its myostatin blocker can best the underwhelming performance of one-time rivals from companies including Novartis.
- Source: fiercebiotech
- 486
- January 4, 2018
blocker Company Insight myostatin SMA
After disappointing 2016, new drug approvals roared back to life in 2017

New drug approvals all but screeched to a halt in 2016, with a measly 22 new OKs after a pair of bountiful years. But the FDA wasted no time in 2017, signing off on 12 drugs in the first quarter alone—besting its record for the same period of any year in recent history.
- Source: fiercebiotech
- 615
- January 4, 2018
CAR-T therapy FDA New Approvals new drug
The Healthcare Technology Winners of 2017

It’s been a big year in healthcare technology. Healthcare Analytics News™ reached out to experts across our 8 coverage areas to determine which companies, people, and projects made the biggest waves. The winners of 2017 ushered in advances that have turned heads, resulted in measurable improvements, and given reason to believe that this high-speed sector is not built on hype alone.
- Source: hcanews
- 484
- January 1, 2018
healthcare technology Market Views
Study explores impact of obesity on bone marrow cells

New research published in the Journal of Experimental Medicine highlights the pernicious effect of obesity on the long-term health of blood-making stem cells (hematopoietic stem cells).
- Source: medicalxpress
- 511
- December 28, 2017
hematopoietic stem cells obesity Researches
Roche snags another Perjeta combo nod, but will ‘weak’ data limit its use?

Analysts and investors think Perjeta’s end-of-the-year indication may not be as lucrative as they once hoped. The FDA green-lighted the drug in tandem with giant Herceptin and chemo for HER2-positive, post-surgery breast cancer patients with a high risk of recurrence. Patients should receive up to 18 cycles of the regimen over the course of one year, according to the indication.
- Source: fiercepharma
- 553
- December 28, 2017
breast cancer Company Insight FDA HER2-positive

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.